[go: up one dir, main page]

AR002719A1 - Forma ii polimorfa 2-metil-4-(4-metil-1-piperacinil)-10h-tieno[2,3-b]-[1,5] benzodiacepina(olanzapina) y formulaciones farmaceuticas que las contienen. - Google Patents

Forma ii polimorfa 2-metil-4-(4-metil-1-piperacinil)-10h-tieno[2,3-b]-[1,5] benzodiacepina(olanzapina) y formulaciones farmaceuticas que las contienen.

Info

Publication number
AR002719A1
AR002719A1 ARP960101876A AR10187696A AR002719A1 AR 002719 A1 AR002719 A1 AR 002719A1 AR P960101876 A ARP960101876 A AR P960101876A AR 10187696 A AR10187696 A AR 10187696A AR 002719 A1 AR002719 A1 AR 002719A1
Authority
AR
Argentina
Prior art keywords
methyl
olanzapine
benzodiacepine
piperacinyl
theno
Prior art date
Application number
ARP960101876A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002719(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002719A1 publication Critical patent/AR002719A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se trata de una nueva forma de 2-metil-4-(4-metil-1-piperacinil)-1OH-tieno [2,3-b][1,5]benzodiacepina (Olanzapina), disponible de otras formas conocidasdel mismo compuesto por difractometría (en polvo) con Rx, cuyos parámetros se detallan en las reivindicaciones y en la memoria descriptiva. Dicho compuestoútil en el tratamiento de estados psicóticos, tiene la fórmula (I). También se proponen formulaciones farmacéuticamente que incluyen dicha forma (II) comocomponente activo.
ARP960101876A 1995-03-24 1996-03-22 Forma ii polimorfa 2-metil-4-(4-metil-1-piperacinil)-10h-tieno[2,3-b]-[1,5] benzodiacepina(olanzapina) y formulaciones farmaceuticas que las contienen. AR002719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
AR002719A1 true AR002719A1 (es) 1998-04-29

Family

ID=23621056

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960101876A AR002719A1 (es) 1995-03-24 1996-03-22 Forma ii polimorfa 2-metil-4-(4-metil-1-piperacinil)-10h-tieno[2,3-b]-[1,5] benzodiacepina(olanzapina) y formulaciones farmaceuticas que las contienen.
ARP960101875A AR010448A1 (es) 1995-03-24 1996-03-22 PROCEDIMIENTO PARA OBTENER LA FORMA II POLIMORFA DE 2-METIL-4-[4-METIL-1- PIPERACINIL]-10H-TIENO-[2,3-b]-[1,5]-BENZODIACEPINA (OLANZAPINA)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP960101875A AR010448A1 (es) 1995-03-24 1996-03-22 PROCEDIMIENTO PARA OBTENER LA FORMA II POLIMORFA DE 2-METIL-4-[4-METIL-1- PIPERACINIL]-10H-TIENO-[2,3-b]-[1,5]-BENZODIACEPINA (OLANZAPINA)

Country Status (48)

Country Link
US (1) US5736541A (es)
EP (3) EP0733635B1 (es)
JP (1) JPH11502535A (es)
KR (1) KR100399688B1 (es)
CN (1) CN1065536C (es)
AP (1) AP828A (es)
AR (2) AR002719A1 (es)
AT (4) ATE331719T1 (es)
AU (1) AU706471B2 (es)
BG (1) BG62619B1 (es)
BR (1) BR9607790A (es)
CA (1) CA2214005C (es)
CH (1) CH690579A5 (es)
CO (1) CO4650278A1 (es)
CZ (1) CZ292688B6 (es)
DE (4) DE69614426T2 (es)
DK (4) DK0733635T3 (es)
EA (1) EA000149B1 (es)
EE (1) EE03489B1 (es)
EG (1) EG23659A (es)
ES (3) ES2208220T3 (es)
FI (1) FI973750L (es)
GB (1) GB2313835B (es)
HU (1) HU224989B1 (es)
IL (1) IL117610A (es)
IS (1) IS1896B (es)
LT (1) LT4349B (es)
LU (1) LU90096B1 (es)
LV (1) LV12018B (es)
MY (1) MY114701A (es)
NO (1) NO314663B1 (es)
NZ (1) NZ306110A (es)
OA (1) OA10510A (es)
PA (1) PA8353701A1 (es)
PE (1) PE44897A1 (es)
PL (1) PL183723B1 (es)
PT (3) PT1095941E (es)
RO (1) RO118872B1 (es)
SE (1) SE9703205L (es)
SI (4) SI9620040B (es)
SK (1) SK284143B6 (es)
SV (1) SV1996000031A (es)
TR (1) TR199701017T1 (es)
TW (2) TW513432B (es)
UA (1) UA44765C2 (es)
WO (1) WO1996030375A1 (es)
YU (1) YU49478B (es)
ZA (2) ZA962342B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1997011700A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Method for treating a tic disorder
BR9708181A (pt) * 1996-03-11 1999-07-27 Lilly Co Eli Método parsa tratamento da insônia
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
PL329221A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Method of relieving hemicrania pains
JP2000507546A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 麻酔方法
NZ332039A (en) * 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
CZ298198A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
TR199900639T2 (xx) * 1996-09-23 1999-06-21 Eli Lilly And Company Olanzapin dihidrat D.
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CZ302367B6 (cs) * 1998-09-30 2011-04-13 Eli Lilly And Company 2-Methylthienobenzodiazepinový prípravek
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
EP1246827B1 (en) * 1999-12-28 2005-04-13 Cipla Limited New polymorphic forms of olanzapine
IL154688A0 (en) * 2000-08-31 2003-09-17 Reddys Lab Ltd Dr Hydrates of olanzapine and processes for the preparation thereof
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
EP1440074A1 (en) * 2001-10-29 2004-07-28 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
AU2002367119A1 (en) * 2001-12-24 2003-07-15 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ES2232332T3 (es) * 2003-03-12 2007-08-16 Teva Pharmaceutical Industries Ltd Composiciones farmaceuticas estables de desloratadina.
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
WO2005063771A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries Ltd Methods of preparing olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
JP4940152B2 (ja) 2005-01-05 2012-05-30 イーライ リリー アンド カンパニー パモ酸オランザピン二水和物
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
AR053562A1 (es) * 2005-03-21 2007-05-09 Reddys Lab Ltd Dr Proceso para la preparacion de la forma i cristalina de olanzapina
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
EP3446565B1 (en) 2010-08-23 2023-11-01 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
EP3581195B1 (en) * 2012-08-21 2025-10-01 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
KR20240130825A (ko) 2022-01-20 2024-08-29 테바 파마슈티컬스 인터내셔널 게엠베하 올란자핀, 이의 조성물 및 이의 사용 방법
LT4554562T (lt) 2023-01-10 2025-12-10 Medincell Sa Olanzapino kompozicijos ir panaudojimo būdai

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
CA2097016A1 (en) * 1992-05-29 1993-11-30 John Fairhurst Pharmaceutical compounds
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
LU90096B1 (fr) 1997-07-22
CA2214005C (en) 2001-07-03
NO314663B1 (no) 2003-04-28
SV1996000031A (es) 1998-03-27
SE9703205D0 (sv) 1997-09-05
ES2208220T3 (es) 2004-06-16
YU17796A (sh) 1999-03-04
IS1896B (is) 2003-10-20
NO974365L (no) 1997-09-22
DE69614426T2 (de) 2002-05-23
RO118872B1 (ro) 2003-12-30
AU706471B2 (en) 1999-06-17
HUP9802824A2 (hu) 1999-06-28
JPH11502535A (ja) 1999-03-02
FI973750A7 (fi) 1997-09-22
AU5427996A (en) 1996-10-16
ATE251627T1 (de) 2003-10-15
CA2214005A1 (en) 1996-10-03
SI0733635T1 (en) 2002-06-30
IL117610A (en) 2001-08-26
EP0733635A1 (en) 1996-09-25
ES2266719T3 (es) 2007-03-01
SE9703205L (sv) 1997-09-05
GB2313835A (en) 1997-12-10
ATE331719T1 (de) 2006-07-15
NZ306110A (en) 1998-09-24
TW442488B (en) 2001-06-23
KR19980703188A (ko) 1998-10-15
HU224989B1 (en) 2006-05-29
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
DK1095941T3 (da) 2004-02-16
PT1095941E (pt) 2004-02-27
HUP9802824A3 (en) 2000-01-28
LV12018A (lv) 1998-04-20
CO4650278A1 (es) 1998-09-03
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
CN1179160A (zh) 1998-04-15
GB9719819D0 (en) 1997-11-19
LV12018B (en) 1998-09-20
EE03489B1 (et) 2001-08-15
MX9707183A (es) 1997-11-29
EP1095941A1 (en) 2001-05-02
SI1445259T1 (sl) 2006-10-31
HK1013988A1 (en) 1999-09-17
DE69630324T2 (de) 2004-07-29
SI1095941T1 (en) 2003-12-31
AT406771B (de) 2000-08-25
EG23659A (en) 2007-03-26
US5736541A (en) 1998-04-07
EP0733635B1 (en) 2001-08-16
EP1095941B1 (en) 2003-10-08
DE19681286T1 (de) 1998-04-02
UA44765C2 (uk) 2002-03-15
GB2313835B (en) 1998-09-16
CZ300097A3 (en) 1997-12-17
YU49478B (sh) 2006-05-25
PL322501A1 (en) 1998-02-02
DK108997A (da) 1997-11-12
BG101900A (en) 1999-03-31
BG62619B1 (bg) 2000-03-31
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
LT4349B (lt) 1998-05-25
IL117610A0 (en) 1996-07-23
PL183723B1 (pl) 2002-07-31
BR9607790A (pt) 1998-07-07
PE44897A1 (es) 1997-10-22
EE9700232A (et) 1998-04-15
ATE204280T1 (de) 2001-09-15
KR100399688B1 (ko) 2004-02-18
DK0733635T3 (da) 2001-10-08
FI973750A0 (fi) 1997-09-22
DE69636313T2 (de) 2007-05-31
OA10510A (en) 2002-04-24
DE69636313D1 (de) 2006-08-10
EA199700262A1 (ru) 1998-02-26
LT97148A (lt) 1998-01-26
IS4564A (is) 1997-09-22
SK284143B6 (sk) 2004-10-05
DK1445259T3 (da) 2006-10-16
ATA902196A (de) 2000-01-15
EA000149B1 (ru) 1998-10-29
TW513432B (en) 2002-12-11
TR199701017T1 (xx) 1998-01-21
PT733635E (pt) 2001-12-28
ZA962342B (en) 1997-09-22
SK121897A3 (en) 1998-03-04
CH690579A5 (de) 2000-10-31
EP1445259B1 (en) 2006-06-28
DE69630324D1 (de) 2003-11-13
AP828A (en) 2000-04-28
EP1445259A1 (en) 2004-08-11
SI9620040B (sl) 2002-02-28
DE69614426D1 (de) 2001-09-20
SI9620040A (sl) 1998-06-30
ES2159346T3 (es) 2001-10-01
CZ292688B6 (cs) 2003-11-12
MY114701A (en) 2002-12-31
FI973750L (fi) 1997-09-22
ZA962344B (en) 1997-09-22
CN1065536C (zh) 2001-05-09

Similar Documents

Publication Publication Date Title
AR002719A1 (es) Forma ii polimorfa 2-metil-4-(4-metil-1-piperacinil)-10h-tieno[2,3-b]-[1,5] benzodiacepina(olanzapina) y formulaciones farmaceuticas que las contienen.
ID28432A (id) Senyawa-senyawa baru
AR014854A1 (es) POLIMORFO CRISTALINO DEL HIDROGENOSULFATO DE CLOPIDROGREL (FORMA2) (+)-(S)-ALFA-(2-CLOROFENIL)-4,5,6,7-TETRAHIDROTIENO[3,2-C]PIRIDINIL-5-ACETATO DE METILO ,PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA QUE LO CONTIENE
WO2002032900A3 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
MY134129A (en) Polymorphs of an epothilone analog
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
AU2003237305A1 (en) Process of preparation of olanzapine form i
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
WO2001038311A3 (en) Pyrimidine derivatives as selective inhibitors of cox-2
IL117971A (en) Pharmaceutical compositions containing olanzapine for treating dyskinesias
NO20013645L (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjon av de perifere benzodiazepinreseptorer
EE200100377A (et) Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena
HUP0002963A3 (en) Use of pyrazolo-[4,3-d] pyrimidinon derivatives for the production of pharmaceutical compositions for treating diseases of the eye field
ATE401332T1 (de) Neue polymorphe von olanzapin-hydrochlorid
SV2001000570A (es) Agente terapeutico cristalino ref. pcs22011afae/bb
DE69624566D1 (de) Behandlung der anorexie
ECSP961694A (es) Procedimeinto para preparar olanzapina (caso x - 9992m)
ECSP961697A (es) Procedimiento y formas cristalinas de 2- metil- tieno- benzodiacepina x-8917a
HUP9902882A2 (hu) Olanzapin alkalmazása álmatlanság kezelésére szolgáló gyógyszerkészítmények előállítására